Binghe Xu1, Yongmei Yin2, Mei Dong1, Yan Song1, Wei Li2, Xiang Huang2, Tongshan Wang2, Jing He2, Xiyan Mu3, Li Li4, Song Mu5, Wa Zhang4, Miao Li4. 1. National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 2. The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. 3. BeiGene (Shanghai) Co., Ltd., Shanghai, China. 4. BeiGene (Beijing) Co., Ltd., Beijing, China. 5. BeiGene USA, Inc., San Mateo, CA, USA.
Abstract
BACKGROUND: The recommended phase 2 dose (RP2D) of pamiparib, an investigational PARP1/2 inhibitor, was established as 60 mg twice daily (BID) in a first-in-human (FIH) study (NCT02361723). METHODS: Chinese patients with advanced non-mucinous high-grade ovarian cancer (HGOC) or triple-negative breast cancer (TNBC) whose disease either progressed despite standard therapy, or for which there is no standard therapy were enrolled in the dose-escalation (DE) portion of a phase 1/2 study (NCT03333915). The primary endpoint was safety/tolerability; secondary objectives were pharmacokinetics and antitumor activity. BRCA1/2 mutation status was retrospectively evaluated. RESULTS: Nine HGOC and six TNBC patients (N = 15; n = 4, 20 mg; n = 4, 40 mg; n = 7, 60 mg) were enrolled; as of 30 September 2019, one HGOC patient remained on treatment. Seven patients (n = 5, HGOC; n = 2, TNBC) had germline BRCA1/2 mutation (gBRCAmut ); all HGOC patients were resistant/refractory to platinum. Asthenia and nausea (n = 12 each) were the most common treatment-related adverse events (TRAEs). Decreased hemoglobin was the most common grade 3 TRAE (n = 3); no grade ≥4 AEs were observed. No dose-limiting toxicities (DLTs) were reported. Pamiparib plasma exposure was similar to exposure observed in the FIH study after a single-dose administration, albeit slightly higher at steady state. Among 13 RECIST-evaluable patients, two with HGOC (gBRCAmut , n = 1) achieved a confirmed partial response and six with HGOC (gBRCAmut , n = 4) achieved stable disease; all TNBC RECIST-evaluable patients (n = 5) reported progressive disease. CONCLUSIONS: Pamiparib was generally well tolerated in Chinese patients, with durable responses observed in patients with HGOC. Based on these results, pamiparib 60 mg BID was confirmed as the RP2D.
BACKGROUND: The recommended phase 2 dose (RP2D) of pamiparib, an investigational PARP1/2 inhibitor, was established as 60 mg twice daily (BID) in a first-in-human (FIH) study (NCT02361723). METHODS: Chinese patients with advanced non-mucinous high-grade ovarian cancer (HGOC) or triple-negative breast cancer (TNBC) whose disease either progressed despite standard therapy, or for which there is no standard therapy were enrolled in the dose-escalation (DE) portion of a phase 1/2 study (NCT03333915). The primary endpoint was safety/tolerability; secondary objectives were pharmacokinetics and antitumor activity. BRCA1/2 mutation status was retrospectively evaluated. RESULTS: Nine HGOC and six TNBC patients (N = 15; n = 4, 20 mg; n = 4, 40 mg; n = 7, 60 mg) were enrolled; as of 30 September 2019, one HGOC patient remained on treatment. Seven patients (n = 5, HGOC; n = 2, TNBC) had germline BRCA1/2 mutation (gBRCAmut ); all HGOC patients were resistant/refractory to platinum. Asthenia and nausea (n = 12 each) were the most common treatment-related adverse events (TRAEs). Decreased hemoglobin was the most common grade 3 TRAE (n = 3); no grade ≥4 AEs were observed. No dose-limiting toxicities (DLTs) were reported. Pamiparib plasma exposure was similar to exposure observed in the FIH study after a single-dose administration, albeit slightly higher at steady state. Among 13 RECIST-evaluable patients, two with HGOC (gBRCAmut , n = 1) achieved a confirmed partial response and six with HGOC (gBRCAmut , n = 4) achieved stable disease; all TNBC RECIST-evaluable patients (n = 5) reported progressive disease. CONCLUSIONS:Pamiparib was generally well tolerated in Chinese patients, with durable responses observed in patients with HGOC. Based on these results, pamiparib 60 mg BID was confirmed as the RP2D.
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Philip Jones; Sergio Altamura; Julia Boueres; Federica Ferrigno; Massimiliano Fonsi; Claudia Giomini; Stefania Lamartina; Edith Monteagudo; Jesus M Ontoria; Maria Vittoria Orsale; Maria Cecilia Palumbi; Silvia Pesci; Giuseppe Roscilli; Rita Scarpelli; Carsten Schultz-Fademrecht; Carlo Toniatti; Michael Rowley Journal: J Med Chem Date: 2009-11-26 Impact factor: 7.446
Authors: J Mateo; C J Lord; V Serra; A Tutt; J Balmaña; M Castroviejo-Bermejo; C Cruz; A Oaknin; S B Kaye; J S de Bono Journal: Ann Oncol Date: 2019-09-01 Impact factor: 32.976
Authors: Hongmei Wang; Meng Wu; Haonan Liu; Hang Zhou; Yang Zhao; Yifan Geng; Bo Jiang; Kai Zhang; Bo Zhang; Zhengxiang Han; Xiuping Du Journal: Front Oncol Date: 2021-11-24 Impact factor: 6.244
Authors: Song Mu; Daniel Palmer; Richard Fitzgerald; Claudia Andreu-Vieyra; Heather Zhang; Zhiyu Tang; Dan Su; Srikumar Sahasranaman Journal: Clin Pharmacol Drug Dev Date: 2021-04-19